<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The genes for acetylcholinesterase (ACHE) and butyrylcholinesterase (BCHE) are located within regions subject to non-random chromosomal abnormalities in the <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) and <z:hpo ids='HP_0011009'>acute</z:hpo> <z:mpath ids='MPATH_342'>myeloid leukaemia</z:mpath> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>Acetylcholinesterase is mapped to 7q22, within the critical deleted region presumed to contain a myeloid specific <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> suppressor gene </plain></SENT>
<SENT sid="2" pm="."><plain>Butyrylcholinesterase is mapped to 3q26: abnormalities at this region are associated with sub-types of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> with <z:hpo ids='HP_0001873'>thrombocytopenia</z:hpo>, or with <z:hpo ids='HP_0001894'>increased platelet counts</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>Both ACHE and BCHE have been implicated as playing a role in megakaryopoiesis and thrombopoiesis, and these genes have been observed to be co-amplified in <z:hpo ids='HP_0011009'>acute</z:hpo> <z:mpath ids='MPATH_342'>myeloid leukaemia</z:mpath> </plain></SENT>
<SENT sid="4" pm="."><plain>Recent findings suggest a more significant role for the ACHE gene in haemopoiesis by regulating multipotent stem cell proliferation, and <z:mpath ids='MPATH_3'>apoptosis</z:mpath> in cells undergoing erythroid and myeloid differentiation </plain></SENT>
<SENT sid="5" pm="."><plain>This led us to investigate gene copy-number alterations at these genes in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>Samples were screened by slot-blot hybridization, and if changes were observed, by Southern blotting </plain></SENT>
<SENT sid="7" pm="."><plain>A total of 42 samples from 31 de novo <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> patients, 10 samples from eight cases of post-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> and 85 samples from 67 MDS patients were analysed with probes for ACHE, BCHE, c-MYC, <z:chebi fb="14" ids="53218">MDR</z:chebi>-1 and <z:chebi fb="0" ids="5386">globin</z:chebi> control </plain></SENT>
<SENT sid="8" pm="."><plain>Changes in ACHE and/or BCHE were observed in 9/31 de novo <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> patients, and in 7/67 MDS patients: 1/37 cases of refractory <z:hpo ids='HP_0001903'>anaemia</z:hpo> (RA), 1/10 cases of refractory <z:hpo ids='HP_0001903'>anaemia</z:hpo> with excess blasts (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>) and 5/20 <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:mpath ids='MPATH_501'>myelomonocytic leukaemia</z:mpath> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e>) patients </plain></SENT>
<SENT sid="9" pm="."><plain>The amplification events observed generated copy numbers no greater than 10, showed <z:mpath ids='MPATH_458'>normal</z:mpath> restriction patterns and had no clear correlation with megakaryopoiesis or thrombopoiesis </plain></SENT>
<SENT sid="10" pm="."><plain>Loss of signal at the ACHE locus was observed: haploid signal intensity was seen in seven samples: one RA with <z:hpo ids='HP_0001873'>thrombocytopenia</z:hpo>, three <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e>, one <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>-M5a (no karyotypic abnormalities of chromosome 7), one <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>-M4 (<z:mp ids='MP_0004026'>monosomy</z:mp> 7), and one case of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>-M7 (karyotype unknown) </plain></SENT>
<SENT sid="11" pm="."><plain>Homozygous deletion was observed at relapse of an additional patient with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>-M4 </plain></SENT>
<SENT sid="12" pm="."><plain>These data reinforce the possibility that ACHE may play a role as a <z:e sem="disease" ids="C0027022" disease_type="Neoplastic Process" abbrv="MPD">myeloid tumour</z:e> suppressor gene </plain></SENT>
</text></document>